title: [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
abstract: Glucagon-like peptide-1 (GLP-1) receptor agonists are a new group of drugs for the treatment of type 2 diabetes mellitus (DM2). In the present article, we review the available evidence on the efficacy of GLP-1 receptor agonists as glucose-lowering agents, their place in therapeutic algorithms, and the clinical factors associated with a favorable treatment response. Finally, we describe the clinical characteristics of patients who may benefit from these drugs.
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición (CIBERobn CB06/003), Instituto de Salud Carlos III, España.
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Fernández-García
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España; Centro de Investigación Biomédica en Red-Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem), Instituto de Salud Carlos III, España. Electronic address: nataliacolomo@gmail.com.
authors.forename: Natalia
authors.initials: N
authors.lastname: Colomo
authors.affiliation: Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, España; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y la Nutrición (CIBERobn CB06/003), Instituto de Salud Carlos III, España.
authors.forename: Francisco José
authors.initials: FJ
authors.lastname: Tinahones
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D050260:Carbohydrate Metabolism / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003245:Consensus Statements as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D057915:Drug Substitution; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000502:physiology*; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D018027:Receptors, Glucagon / Q000819:agonists*; D013030:Spain
chemical_list: D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D018027:Receptors, Glucagon; C000593833:GLP1R protein, human
keywords: Agonista del receptor del péptido similar al glucagón; Diabetes; Diabetes mellitus; Efficacy; Eficacia; Exenatida; Exenatida semanal; Exenatide; Glucagon-like peptide-1 receptor agonist; Hipertensión; Hipoglucemias; Hypertension; Hypoglycemias; Liraglutida; Liraglutide; Lixisenatida; Lixisenatide; Obesidad; Obesity; Weekly exenatide